146 related articles for article (PubMed ID: 22561556)
1. Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial.
Jones ML; Martoni CJ; Di Pietro E; Simon RR; Prakash S
Regul Toxicol Pharmacol; 2012 Jul; 63(2):313-20. PubMed ID: 22561556
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: a randomized, placebo-controlled, double-blind study.
Jones ML; Martoni CJ; Tamber S; Parent M; Prakash S
Food Chem Toxicol; 2012 Jun; 50(6):2216-23. PubMed ID: 22425689
[TBL] [Abstract][Full Text] [Related]
3. Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial.
Jones ML; Martoni CJ; Prakash S
J Clin Endocrinol Metab; 2013 Jul; 98(7):2944-51. PubMed ID: 23609838
[TBL] [Abstract][Full Text] [Related]
4. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults.
Jones ML; Martoni CJ; Parent M; Prakash S
Br J Nutr; 2012 May; 107(10):1505-13. PubMed ID: 22067612
[TBL] [Abstract][Full Text] [Related]
5. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial.
Jones ML; Martoni CJ; Prakash S
Eur J Clin Nutr; 2012 Nov; 66(11):1234-41. PubMed ID: 22990854
[TBL] [Abstract][Full Text] [Related]
6. Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial.
Jones ML; Martoni CJ; Ganopolsky JG; Sulemankhil I; Ghali P; Prakash S
Expert Opin Biol Ther; 2013 Dec; 13(12):1643-51. PubMed ID: 24074303
[TBL] [Abstract][Full Text] [Related]
7. Changes in bile acids, FGF-19 and sterol absorption in response to bile salt hydrolase active L. reuteri NCIMB 30242.
Martoni CJ; Labbé A; Ganopolsky JG; Prakash S; Jones ML
Gut Microbes; 2015; 6(1):57-65. PubMed ID: 25612224
[TBL] [Abstract][Full Text] [Related]
8. Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread.
Dommels YE; Kemperman RA; Zebregs YE; Draaisma RB; Jol A; Wolvers DA; Vaughan EE; Albers R
Appl Environ Microbiol; 2009 Oct; 75(19):6198-204. PubMed ID: 19684171
[TBL] [Abstract][Full Text] [Related]
9. Intravaginal administration of gelatine capsules containing freeze-dried autochthonous lactobacilli: a double-blind, randomised clinical trial of safety.
De Gregorio PR; Maldonado NC; Pingitore EV; Terraf MCL; Tomás MSJ; de Ruiz CS; Santos V; Wiese B; Bru E; Paiz MC; Reina MF; Schujman DE; Nader-Macías MEF
Benef Microbes; 2020 Feb; 11(1):5-17. PubMed ID: 32066254
[TBL] [Abstract][Full Text] [Related]
10. The effect of orally administered probiotic Lactobacillus reuteri-containing tablets in peri-implant mucositis: a double-blind randomized controlled trial.
Flichy-Fernández AJ; Ata-Ali J; Alegre-Domingo T; Candel-Martí E; Ata-Ali F; Palacio JR; Peñarrocha-Diago M
J Periodontal Res; 2015 Dec; 50(6):775-85. PubMed ID: 25712760
[TBL] [Abstract][Full Text] [Related]
11. Limosilactobacillus reuteri consumption significantly reduces the total cholesterol concentration without affecting other cardiovascular disease risk factors in adults: A systematic review and meta-analysis.
Liu J; Zhu R; Song J; Sohaib M; Wang S; Mao J; Qi J; Xiong X; Zhou W; Guo L
Nutr Res; 2023 Sep; 117():1-14. PubMed ID: 37419064
[TBL] [Abstract][Full Text] [Related]
12. Lactobacillus reuteri supplements do not affect salivary IgA or cytokine levels in healthy subjects: A randomized, double-blind, placebo-controlled, cross-over trial.
Jørgensen MR; Keller MK; Kragelund C; Hamberg K; Ericson D; Nielsen CH; Twetman S
Acta Odontol Scand; 2016 Jul; 74(5):399-404. PubMed ID: 27104984
[TBL] [Abstract][Full Text] [Related]
13. Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study.
Francavilla R; Polimeno L; Demichina A; Maurogiovanni G; Principi B; Scaccianoce G; Ierardi E; Russo F; Riezzo G; Di Leo A; Cavallo L; Francavilla A; Versalovic J
J Clin Gastroenterol; 2014; 48(5):407-13. PubMed ID: 24296423
[TBL] [Abstract][Full Text] [Related]
14. The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial.
Hsieh MC; Tsai WH; Jheng YP; Su SL; Wang SY; Lin CC; Chen YH; Chang WW
Sci Rep; 2018 Nov; 8(1):16791. PubMed ID: 30429496
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of Lactobacillus reuteri DSM 17938 and effects on biomarkers in healthy adults: results from a randomized masked trial.
Mangalat N; Liu Y; Fatheree NY; Ferris MJ; Van Arsdall MR; Chen Z; Rahbar MH; Gleason WA; Norori J; Tran DQ; Rhoads JM
PLoS One; 2012; 7(9):e43910. PubMed ID: 22970150
[TBL] [Abstract][Full Text] [Related]
16. Oral Microbiota Shift after 12-Week Supplementation with Lactobacillus reuteri DSM 17938 and PTA 5289; A Randomized Control Trial.
Romani Vestman N; Chen T; Lif Holgerson P; Öhman C; Johansson I
PLoS One; 2015; 10(5):e0125812. PubMed ID: 25946126
[TBL] [Abstract][Full Text] [Related]
17. Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial.
Sung V; Hiscock H; Tang ML; Mensah FK; Nation ML; Satzke C; Heine RG; Stock A; Barr RG; Wake M
BMJ; 2014 Apr; 348():g2107. PubMed ID: 24690625
[TBL] [Abstract][Full Text] [Related]
18. Lactobacillus reuteri for Infants with Colic: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Fatheree NY; Liu Y; Taylor CM; Hoang TK; Cai C; Rahbar MH; Hessabi M; Ferris M; McMurtry V; Wong C; Vu T; Dancsak T; Wang T; Gleason W; Bandla V; Navarro F; Tran DQ; Rhoads JM
J Pediatr; 2017 Dec; 191():170-178.e2. PubMed ID: 28969890
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic syndrome: a randomized clinical trial (PROSIR).
Tenorio-Jiménez C; Martínez-Ramírez MJ; Tercero-Lozano M; Arraiza-Irigoyen C; Del Castillo-Codes I; Olza J; Plaza-Díaz J; Fontana L; Migueles JH; Olivares M; Gil Á; Gomez-Llorente C
BMC Complement Altern Med; 2018 Nov; 18(1):306. PubMed ID: 30453950
[TBL] [Abstract][Full Text] [Related]
20. The Efficacy and Safety of the Probiotic Bacterium Lactobacillus reuteri DSM 17938 for Infantile Colic: A Meta-Analysis of Randomized Controlled Trials.
Xu M; Wang J; Wang N; Sun F; Wang L; Liu XH
PLoS One; 2015; 10(10):e0141445. PubMed ID: 26509502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
